The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -7,368,325 |
| Depreciation | 43,324 |
| Amortization | 39,548 |
| Amortization of rou asset | 0 |
| Amortization of capitalized share-based payments | 176,471 |
| Share-based compensation under equity incentive plan | 279,873 |
| Change in fair value of derivative liabilities | 266,089 |
| Write-offs of capitalized patents | 0 |
| Change in inventory reserve | 251,677 |
| Accounts receivable | 22,896 |
| Prepaid and other assets | 19,486 |
| Inventory | 465,837 |
| Accounts payable and accrued liabilities | 491,083 |
| Accrued interest, net | -11,635 |
| Reduction of lease liability | 0 |
| Net cash used in operating activities | -6,849,022 |
| Capitalization of patents | 55,533 |
| Purchases of fixed assets | 139,881 |
| Acquisition of intangibles | 22,670 |
| Purchase of short-term investments | 1,235,000 |
| Maturities of short-term investments | 1,708,000 |
| Net cash provided by (used in) investing activities | 254,916 |
| Net proceeds from january 2024 offering | 0 |
| Net proceeds from january 2025 offering | 804,346 |
| Net proceeds from february 2025 offering | 908,627 |
| Net proceeds from july 2025 offering | 4,281,300 |
| Shares withheld for net share settlement of performance bonuses | 18,000 |
| Net proceeds from atm offering | 458,614 |
| Net proceeds from private placement | 0 |
| Proceeds from exercise of pre-funded warrants | 2,804 |
| Net cash provided by financing activities | 6,437,691 |
| Effect of exchange rate changes on cash | 7,127 |
| Change in cash and cash equivalents | -149,288 |
| Cash and cash equivalents-beginning of period | 1,659,353 |
| Cash and cash equivalents-end of period | 1,510,065 |
60 DEGREES PHARMACEUTICALS, INC. (SXTPW)
60 DEGREES PHARMACEUTICALS, INC. (SXTPW)